Novan Announces Statistically Significant Phase 2 Clinical Trial Results for SB206

  • Number of Patients with Complete Clearance of Genital Warts Provides Clinical Evidence of Nitric Oxide Anti-Viral Activity Against HPV

  • Company Plans End-of-Phase 2 Meeting for First Half of 2017

Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced top-line results from the Company’s Phase 2 clinical trial with SB206 for the treatment of  genital warts caused by human papillomavirus, or HPV. The highest dose tested, SB206 12%, demonstrated a statistically significant improvement (p<0.05) in the incidence of complete clearance of all baseline warts compared to vehicle treatment after 12 weeks in both the intent-to-treat and per-protocol analyses.